Clinical trials: Influenza A
Signs and Symptoms, Respiratory
Effects of a Yeast Fermentate (EpiCor) Supplement on Cold or Flu Symptoms in Healthy Children
This is a double-blind, randomized, placebo-controlled study. The purpose of the clinical study is to determine the difference between 84 days of once daily oral EpiCor supplementation compared to placebo on the incidence of cold…
- Trial name
- NCT05492370
- Testing
- EpiCor
- Where
- Canada
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- Cargill
Prophylaxis of Avian Influenza
Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years
Evaluate the immune response and reactogenicity of H5N1 vaccination in subjects aged 6 months to 17 years compared to seasonal flu vaccination
- Trial name
- NCT00537524
- Testing
- H5N1 Influenza Vaccine
- Where
- Finland
- Volunteers
- 471 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Swine-Origin Influenza A H1N1 Virus
Drug Use Investigation for Cell-culture Derived Influenza A (H1N1) Emulsion HA Vaccine
This is to evaluate safety of cell-derived A/H1N1 influenza HA vaccine in healthy Japanese subjects.
- Trial name
- NCT01098786
- Testing
- Cell-derived A/H1N1 influenza HA vaccine
- Where
- Japan
- Volunteers
- 556 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza Prevention
The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine
Live Attenuated freeze-dried Influenza Vaccine has been licensed for use in 2020 (Approval No.S20200002), the sponsor of this research submitted an new application for non freeze-dried Live Attenuated Influenza Vaccine in 2021.
- Trial name
- NCT05284851
- Testing
- Live Attenuated Influenza Vaccine(non freeze-dried), Live Attenuated Influenza Vaccine(freeze-dried)
- Where
- China
- Volunteers
- 2,520 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Moderate to Severe Asthma
Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma
This is a Phase 3b, multicenter, randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of tezepelumab (210 mg subcutaneous [SC] every 4 weeks [Q4W]) on antibody responses…
- Trial name
- VECTOR (NCT05062759)
- Testing
- Tezepelumab
- Where
- 15 sites in United States
- Volunteers
- 70 people
- Sponsor
- AstraZeneca
Influenza
Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months
The primary objective of the study was to determine if intranasally administered influenza virus vaccine, CAIV-T), when administered concomitantly with a subcutaneously administered combination live, attenuated mumps, measles…
- Trial name
- NCT00192166
- Testing
- CAIV-T
- Where
- Singapore
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.
This is a study to evaluate the efficacy and safety of a single dose of intravenous peramivir versus placebo in adolescents and adults with acute uncomplicated influenza.
- Trial name
- NCT01224795
- Testing
- Peramivir
- Where
- 96 sites in United States
- Sponsor
- BioCryst Pharmaceuticals
Influenza, Human
Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines
This study will evaluate the efficacy, safety and immunogenicity of one or two 0.25 mL or 0.5 mL intramuscular injections of an adjuvanted influenza vaccine compared with non-influenza and non-adjuvanted influenza control…
- Trial name
- NCT00644059
- Testing
- Adjuvanted trivalent inactivated subunit influenza vaccine, Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine, Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine
- Where
- 101 sites in Finland, Germany and 1 more
- Volunteers
- 4,902 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza
FLU A+B Nasal Swab Clinical Study
The purpose of this clinical study is to obtain clearance for the nasal swab sample type by demonstrating the performance characteristics of the FLU A+B Test versus standard laboratory culture for Influenza A and B viruses using…
- Trial name
- FLUA+B (NCT00636662)
- Testing
- Non-invasive diagnostic testing
- Where
- 5 sites in United States, Canada
- Volunteers
- 800 people
- Sponsor
- Response Biomedical Corp.
Influenza
Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine,(CAIV-T), in Children Who Attend Day Care. (Final Report Version 2.0)
To assess whether CAIV-T was transmitted from vaccinated children to their unvaccinated contacts in a day care setting; and if so, to estimate the rate of transmission.
- Trial name
- NCT00192361
- Testing
- CAIV-T
- Where
- Finland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza Caused by the Novel Influenza A (H1N1) Virus
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children
The purpose of this study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy children.
- Trial name
- NCT00940108
- Testing
- CSL425
- Where
- 5 sites in Australia
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza A, Influenza B
Detection of Influenza A, Influenza B, and RSV Using the Liat™ Assays on the Liat™ Analyzer
The objective of this study is to evaluate the clinical sensitivity and specificity of the Liat™ Influenza A/B \& RSV Assay and the Liat™ Influenza A/B Assay when used on the Liat Analyzer to detect the presence or absence of…
- Conditions
- Influenza A, Influenza B, Respiratory Syncytial Virus (RSV)
- Trial name
- NCT02067286
- Where
- 8 sites in United States
- Volunteers
- 1,642 people
- Sponsor
- IQuum, Inc.
Influenza
Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months
This a multicenter phase II trial will evaluate safety and immunogenicity of two 0.25 mL or 0.5 mL doses of investigational influenza vaccine and active control influenza vaccine in healthy children aged 6 to <60 months.
- Trial name
- NCT00649883
- Testing
- Influenza Trivalent Inactivated vaccines Novartis, Influenza Trivalent Inactivated vaccines
- Where
- 5 sites in Guatemala
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive, Bronchospasm
Prophylactic Efficacy of Relenza Against Influenza A and B
In response to the European regulatory authorities, GSK is conducting a post-marketing observational study to assess the efficacy of Relenza when used as prophylaxis against influenza. SPECIFIC AIMS 1.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Bronchospasm, Influenza, Human, Asthma
- Trial name
- NCT01156701
- Testing
- Receiving a prescription of Relenza for prophylaxis, No prophylaxis with Relenza
- Volunteers
- 171,705 people
- Sponsor
- GlaxoSmithKline
Influenza, Human
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
This is a study to assess the immune (antibody) response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US licensed 2016/2017 Quadrivalent Influenza Vaccine…
- Trial name
- NCT02914275
- Testing
- Seqirus Quadrivalent Inactivated Influenza Vaccine, Comparator Quadrivalent Inactivated Influenza Vaccine
- Where
- 39 sites in United States
- Volunteers
- 2,250 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Immunogenicity and Safety of AdimFlu-S, Formulation 2010-2011, in Infants Aged Between 6-12months Old
The purpose of this study is to evaluate the antibody response to each of the three influenza vaccine strains included in the seasonal flu vaccine(AdimFlu-S), as measured by hemagglutination inhibition (HAI) at 4 weeks after two…
- Trial name
- NCT01355172
- Testing
- AdimFlu-S
- Where
- Taiwan
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
COVID-19, Influenza A
Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.
This study is designed as a prospective, multicentric, sample collection study. The collected samples will be used for diagnostic research, product development and validation of the Panbio™ COVID-19/ Flu A\&B Rapid Panel for the…
- Conditions
- COVID-19, Influenza A, Influenza Type B
- Trial name
- NCT05354115
- Testing
- Nasal and Nasopharyngeal Sampling of the Panbio™ COVID-19/ Flu A&B Rapid Panel
- Where
- United States
- Volunteers
- 676 people
- Sponsor
- Abbott Rapid Dx
Influenza, Human, Pregnancy
Afluria Pregnancy Registry
The study is a population based prospective cohort study designed to collect data on pregnancy outcomes and events of interest among women immunized with Afluria during pregnancy.
- Conditions
- Influenza, Human, Pregnancy, Birth Defect
- Trial name
- NCT03442582
- Testing
- Afluria Influenza Vaccine
- Where
- United States
- Volunteers
- 490 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms
This study will evaluate the safety, pharmacokinetics and efficacy of baloxavir marboxil in healthy pediatric participants from birth to <1 year with influenza like symptoms
- Trial name
- NCT03653364
- Testing
- Baloxavir Marboxil
- Where
- 27 sites in United States, Bulgaria and 7 more
- Volunteers
- 49 people
- Sponsor
- Hoffmann-La Roche
Influenza, Human
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
This phase 3 clinical study is a randomized, observer-blind, comparator-controlled, multicenter study of QIVc versus a US-licensed comparator QIV in children 6 months through 47 months of age.
- Conditions
- Influenza, Human, Virus Diseases
- Trial name
- NCT04074928
- Testing
- QIVc, Comparator QIV
- Where
- 47 sites in United States
- Volunteers
- 2,414 people, healthy volunteers welcome
- Sponsor
- Seqirus